Ou se connecter avec
Twitter Twitter
Facebook Facebook
Apple Apple     
Ou se connecter avec
Twitter Twitter
Facebook Facebook
Apple Apple     


Cours en clôture Korea Stock Exchange  -  30/09/2022
175500.00 KRW   +2.63%
28/09Les actions et le won sud-coréens chutent en raison des craintes de récession
05/09Les actions sud-coréennes terminent à leur plus bas niveau depuis plus de six semaines en raison des inquiétudes concernant l'énergie en Europe.
16/08Celltrion, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2022
SynthèseToute l'actualitéAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur CELLTRION, INC.
28/09Celltrion's Oncology Drug Gets Marketing Authorization in Japan
28/09S.Korean shares, won tumble on recession fears
22/09Celltrion, Abpro Partner to Develop, Commercialize Breast Cancer Treatment Drug
20/09Britain’s MHRA Clears Celltrion's Cancer Drug Vegzelma for Marketing in the UK
07/09PTAB Institutes IPRs Of Tocilzumab Patents Challenged By Celltrion
05/09S.Korean shares end at over six-week low on Europe energy worries
16/08Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
15/08Infliximab Clinical Trial Updates
09/08Celltrion Files IND With FDA For Adalimumab Biosimilar
08/08Celltrion's Net Income Jumps 41.2% in June Quarter
05/08S.Korean shares post third straight weekly gain
05/08Celltrion : 2Q 2022 Earnings Release_Celltrion Inc.
26/07Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
26/07Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
22/07Celltrion, Inc.'s Equity Buyback announced on May 18, 2022, has closed with 500,000 sha..
19/07Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle Eas..
27/06Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Age..
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50..
25/05MÄRKTE ASIEN/Breite Erholung - Tokio mit Konjunktursorgen etwas leichter
25/05MÄRKTE ASIEN/Freundlich - Gelegenheitskäufe nach jüngstem Rücksetzer
18/05Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
18/05Celltrion, Inc. authorizes a Buyback Plan.
16/05Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
13/05Celltrion's Net Profit Falls 39.2% in Q1; Shares Slip 6%
28/04Celltrion To Enter U.S. Humira Biosimilar Market Following Patent Agreement With AbbVie
27/04MÄRKTE ASIEN/Tokio und Seoul schwach - Erholungsrally in Schanghai
27/04MÄRKTE ASIEN/Uneinheitlich - Chinesische Börsen knapp im Plus
26/04MÄRKTE ASIEN/Flaue Erholung - Schanghai weiter im Lockdown-Tief
26/04MÄRKTE ASIEN/Börsen auf moderatem Erholungskurs
19/04Celltrion's CT-P6 Demonstrates Equivalent Safety, Efficacy With HERCEPTIN
18/04Celltrion Healthcare Starts Selling Chronic Inflammatory Disease Biosimilar Yuflyma in ..
07/04Regeneron's Disclaimer Of Aflibercept Formulation Patent Causes PTAB Denial Of Institut..
05/04Celltrion Announces Agreement With Brazilian Government To Supply Infliximab Biosimilar
01/04Regeneron Disclaims An Aflibercept Formulation Patent In Response To Celltrion PGR
29/03Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on February 21, 2022.
25/03Celltrion, Inc.'s Equity Buyback announced on February 21, 2022, has expired with 507,9..
24/03South Korea’s Kospi Falls on Higher Energy Costs, Geopolitical Woes; Samsung Elec..
22/03El Kospi de Corea sube un 0,9%, liderado por los valores de la automoción y la construc..
14/03Celltrion Shares Rally After Regulators' Ruling
08/03Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
02/03FDA warns against use of certain unauthorized COVID antigen tests
24/02El Kospi de Corea cae un 2,6% por el ataque ruso a Ucrania -- Market Talk
21/02Celltrion, Inc. announces an Equity Buyback for 507,937 shares.
21/02Celltrion, Inc. authorizes a Buyback Plan.
17/02South Korea’s Kospi Gains on US Fed’s Decision to Not Focus on Pace of Rate..
17/02Celltrion's Net Income Surges 57.3% in Q4 2021
16/02Celltrion : FY2021, 4Q21 Earning Release_Celltrion Inc.
15/02Celltrion's Biosimilar Remsima Sales Reach New High in 2021 in the US
03/02U.S. to cover cost of over-the-counter COVID tests through Medicare
21/01Three South Korean Firms to Manufacture Low-Cost Variants of Merck's COVID-19 Pill
21/01Fosun Pharma, Other Chinese Drugmakers Rise After Deal to Make Merck's Covid-19 Pill
05/01Celltrion to Start Worldwide Trials of Inhalable COVID-19 Treatment; Shares Decline 3%
04/01South Korean Stocks Close Marginally Higher on Investors’ Wait-and-See Stance; LG..
04/01Celltrion's COVID-19 Treatment Drug Demonstrates Safety in Clinical Trial
2021Ema approva trattamenti contro Covid-19 di Gsk-Vir e Sobi
2021U.S. Omicron plan: boosters, free at-home tests, tighter travel rules
2021Celltrion signs COVID-19 antibody therapy supply deals with Europe
2021MÄRKTE ASIEN/Hongkong schwach - Sydney freundlich
2021U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 billion
2021MÄRKTE ASIEN/Börsen im Wartemodus uneinheitlich
2021MÄRKTE ASIEN/Hongkong fest - Sydney schwächer
2021Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First M..
2021MÄRKTE ASIEN/Etwas fester - Chinas Börsen hinken hinterher
2021MÄRKTE ASIEN/Uneinheitlich - Anleger warten auf Xi Jinping und Biden
2021Celltrion Inc. Shares Rally After EU Approves Marketing of Its Covid-19 Treatment
2021European Commission Approves Celltrion's Antibody COVID-19 Treatment
2021Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
2021S.Korea stocks end 1% higher on chip, biopharma boost, U.S. data in focus
2021S&P Upgrades ITV To Stable From Negative On Expected Revenue Recovery
2021EC Formally Authorises COVID-19 Drugs From Regeneron-Roche, Celltrion
2021MÄRKTE ASIEN/Börsen steigen - China hinkt hinterher
2021MÄRKTE ASIEN/Börsen überwiegend im Plus - Fokus auf China
2021EU Drug Regulator Backs COVID-19 Therapy from South Korea's Celltrion
2021CORONA-BLOG/EU-Kommission will Vorbereitung für Verschärfung der Lage
2021Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First M..
2021EMA macht Weg frei für zwei neue Covid-Medikamente
2021Ema : via libera a 2 nuove cure contro il Covid-19
2021CORONA-BLOG/Österreich verschärft Corona-Maßnahmen weiter
2021EU-Ausschuss empfiehlt Zulassung von Roche-Covid-Medikament Ronapreve
2021CORONA-BLOG/EU-Behörde lässt Antikörper-Behandlungen gegen Covid-19 zu
2021South Korea's Kospi Closes Lower as Inflation Hits Three-Decade High in US; Celltrion L..
2021Celltrion's Net Profit Plunges 20% in Q3
2021Celltrion : 3Q 2021 Earnings Release_Celltrion Inc.
2021EU Poised To Approve Two COVID-19 Antibody Drugs
2021La UE se dispone aprobar los primeros medicamentos de anticuerpos para el COVID
2021Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
2021Amid spike in cases, EU to shortly approve first COVID antibody drugs - sources
2021Eu drugs regulator soon to approve use of regeneron-roche and celltrion monoclonal anti..
2021South Korea Stocks Inch Up as Investors Await US, China Inflation Data; SK Hynix Adds 1..
2021South Korea Stocks Decline as Investors Eye US, China Inflation Data; Biopharma Stocks ..
2021S.Korean stocks end at near 1-month low as biopharma shares slump
2021Private S.Korea firms plan $5.4 billion investment to create vaccine hub
2021Usa : al lavoro per aumentare fornitura test rapidi Covid-19
2021La UE evalúa la autorización del cóctel de anticuerpos COVID-19 de Regeneron y Roche
2021EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
2021U.S. to invest another $1 bln in rapid COVID-19 tests
2021Covid : Ema valuta autorizzazione immissione in commercio Regkirona
2021Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 P..
2021EU signs joint procurement deal for Eli Lilly COVID-19 treatment
2021180 Life Sciences : Plans Supply Deal With Celltrion Healthcare For An..
Prochain événement sur CELLTRION, INC.